The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, called Wegovy HD, for weight loss and long-term maintenance of weight loss for certain adult patients.
The decision was granted just 54 days after filing and represented the fourth approval under the Commissioner’s National Priority Voucher (CNPV) pilot program. “The new FDA is moving with unprecedented efficiency on products that advance national priorities,” said FDA Commissioner Martin Makary, M.D., M.P.H.
“Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.” Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. The new higher dose of Wegovy is indicated to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition.
The approval of a new higher dose will provide adult patients with an additional therapeutic option offering the potential for greater weight loss.
FDA News Releases published a clinical update in Research Highlights on 19 Mar 2026.
The item focuses on FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide.
Review the original article for the full source wording and details.